BCDA has 36-month beta value of 1.28. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BCDA is 3.80M, and currently, short sellers hold a 2.73% ratio of that float. The average trading volume of BCDA on December 20, 2024 was 68.90K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BCDA) stock’s latest price update
BioCardia Inc (NASDAQ: BCDA)’s stock price has dropped by -8.00 in relation to previous closing price of 2.00. Nevertheless, the company has seen a loss of -15.21% in its stock price over the last five trading days. globenewswire.com reported 2024-12-04 that SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the successful completion of a consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) on the next steps for the submission for registration of its lead therapeutic asset, BCDA-01, for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
BCDA’s Market Performance
BCDA’s stock has fallen by -15.21% in the past week, with a monthly drop of -9.36% and a quarterly drop of -27.56%. The volatility ratio for the week is 9.88% while the volatility levels for the last 30 days are 8.41% for BioCardia Inc The simple moving average for the past 20 days is -15.63% for BCDA’s stock, with a -49.69% simple moving average for the past 200 days.
BCDA Trading at -20.35% from the 50-Day Moving Average
After a stumble in the market that brought BCDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.95% of loss for the given period.
Volatility was left at 8.41%, however, over the last 30 days, the volatility rate increased by 9.88%, as shares sank -7.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.34% lower at present.
During the last 5 trading sessions, BCDA fell by -15.21%, which changed the moving average for the period of 200-days by -72.34% in comparison to the 20-day moving average, which settled at $2.18. In addition, BioCardia Inc saw -81.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCDA starting from GILLIS EDWARD M, who proposed sale 3,257 shares at the price of $2.03 back on Dec 17 ’24. After this action, GILLIS EDWARD M now owns shares of BioCardia Inc, valued at $6,611 using the latest closing price.
Altman Peter, the President and CEO of BioCardia Inc, purchase 250 shares at $2.22 during a trade that took place back on Dec 05 ’24, which means that Altman Peter is holding 105,581 shares at $555 based on the most recent closing price.
Stock Fundamentals for BCDA
Current profitability levels for the company are sitting at:
- -109.35 for the present operating margin
- -3.46 for the gross margin
The net margin for BioCardia Inc stands at -108.76. The total capital return value is set at -2.27. Equity return is now at value -737.89, with -154.22 for asset returns.
Currently, EBITDA for the company is -11.56 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 64.09. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.78.
Conclusion
To put it simply, BioCardia Inc (BCDA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
